An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
Clinical trial NCT01498445 · TERMINATED
Trial details
- NCT number
- NCT01498445
- Sponsor
- M.D. Anderson Cancer Center
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-06-12
- Primary completion
- 2019-09-24
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.